Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Move aligns global biologics identity under the Biocon Biologics brand
Safety was equally impressive. ENV-294 was well tolerated
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Phase I to supply clean energy to five facilities, with long-term plans to power 19 hospitals through a 30 MW renewable network
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Board approves five-year appointment, subject to shareholder nod through postal ballot
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Subscribe To Our Newsletter & Stay Updated
